Journal article
Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
- Publication status:
- Published
- Peer review status:
- Reviewed (other)
Actions
Authors
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Lancet Rheumatology Journal website
- Volume:
- 2
- Issue:
- 11
- Pages:
- e653-e655
- Publication date:
- 2020-09-04
- Acceptance date:
- 2020-09-01
- DOI:
- EISSN:
-
2665-9913
- Pmid:
-
33521660
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1135737
- Local pid:
- pubs:1135737
- Deposit date:
- 2021-08-04
Terms of use
- Copyright holder:
- Robinson et al.
- Copyright date:
- 2020
- Rights statement:
- © 2020 Elsevier Ltd. All rights reserved.
- Notes:
-
This is the accepted manuscript version of the article. The final version is available from Elsevier at https://doi.org/10.1016/S2665-9913(20)30309-X
If you are the owner of this record, you can report an update to it here: Report update to this record